Clinical, histological and molecular reversibility of zidovudine myopathy.
The use of zidovudine in the treatment of human immunodeficiency virus infection has been associated with toxic mitochondrial myopathy. There are some reported cases of improvement after stopping the drug, but in only one were molecular studies performed. We therefore studied three patients with toxic AZT myopathy during AZT treatment and after drug withdrawal. Clinical complaints disappeared within the next three months after drug cessation. In all cases, histological data of mitochondrial abnormalities also disappeared. Molecular studies showed an initial depletion of the total amount of mitochondrial DNA with respect to healthy controls which was reversible after AZT withdrawal. This work demonstrates that AZT myopathy is reversible not only at a clinical and histological, but also at a molecular level.
Masanés
F
F
Department of Medicine, IDIBAPS, Hospital Clínic, University of Barcelona, Spain.
Barrientos
A
A
Cebrián
M
M
Pedrol
E
E
Miró
O
O
Casademont
J
J
Grau
J M
JM
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017240:Mitochondrial Myopathies / Q000139:chemically induced* / Q000473:pathology; D013375:Substance Withdrawal Syndrome; D016896:Treatment Outcome; D015215:Zidovudine / Q000009:adverse effects*
D019380:Anti-HIV Agents; D015215:Zidovudine